alpha-Amanitin

DGAP-News: Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2020

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Gene expression, Nucleic acids, Biology, Amatoxin, RNA polymerase II, Messenger RNA, RNA polymerase, Transcription, Polymerase, Amanitin, alpha-Amanitin, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.

Key Points: 
  • Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules.
  • They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells.
  • This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

DGAP-News: Heidelberg Pharma to Present at the Upcoming Virtual European Biotech Investor Day 2020

Retrieved on: 
Wednesday, June 24, 2020
Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Antineoplastic drugs, alpha-Amanitin, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma

Ladenburg, Germany, 24 June 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that Prof Andreas Pahl, Chief Scientific Officer, plans to present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020 , taking place on 25th June 2020 and hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.

Key Points: 
  • Ladenburg, Germany, 24 June 2020 - Heidelberg Pharma AG (FSE: HPHA) today announced that Prof Andreas Pahl, Chief Scientific Officer, plans to present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020 , taking place on 25th June 2020 and hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.
  • Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.